Lecture 16- Chromosomes in Cancer Flashcards
Philadelphia Chromosome
Myeloid Leukaemia
Haematopoiesis
all arises from haematopoetic stem cell
Leukaemia -
Stem Cell cancers and then problems arise further down
2 types of Leukaemia
Either lymphoid or myeloid
-Lymphomas or myeloproliferative disorders
What dictates the cancer and the prognosis ?
Stage in the cell it matures in dictates the cancer and the prognosis the later it occurs in the cell the worse the prognosis
Multiple Myeloma
of the plasma cells
What is the more common form of Leukaemia ?
Myeloid leukaemia more common – more cell types involved > granulocytes eg eosinophils, basophils, neutrophils
-Accumulation of the immature cell types – myeloid progenitor induced to produce more cells but they don’t mature – blasts are cells that haven’t matured
Genetic Changes in Leukaemia
Loss of chromosome material
Gain of chromosome material – duplication, amplification and trisomy
Altered gene expression – gene fusion, juxtaposed (next to new gene control)
DNA mutation – point, splice, frameshift, deletion, duplication
Testing for Chromosome Abnormalities
Cytogenetics – study of genetic material and chromosome level
Karyotype – whole genome scan
Fish
Preparation of the karyotype
Want chromosomes at metaphase – add colcemid
Sample > Culture medium > Incubate 37> Add colcemid > Add hypotonic sol > Fix cells > stain> Banding > Karotyping
Dark bands
AT rich, late replication, gene poor, heterochromatic
Light Bands
GC rich early replicating, gene rich
Euchromatic
Trypsin produces…
Dark and light bands
Karyotype analysis
Analysis- count and pair chromosomes
Match up bands look for absent/extra
Types of chromosome abnormalities
- Trisomy
- Monosomy
- Inversion
- Insertion – chunk of one chromosome into another
- Translocation – swap of chromosome from one to the other
Chromosome nomenclature
Long arm q Short arm p Each band assigned a number e.g 3p21 46 chromosomes Autosomes 1-22 and sex chromosomes – XX or XY total number, sex ,abnormality
Fusion genes
breakpoint occurs with the two genes and forms a hybrid
Deregulation
juxtaposition to a regulating gene altered regulation
Detection –
- Translocation and inversions via karyotype
- Some gene fusions are caused by subkarotypic rearrangements
- Clinical need for rapid confirmation of gene fusion – prognostic and treatment implication
- FISH
FISH
Fluorescently labelled DNA probes
Detect monosomy trisomy deletions duplication, amplification and rearrangement s
Probe is ssDNA probe
Probe on slide cover with cover slip and then hybridise over night
Types of FISH probe
- Whole chromosome paints
- Locus specific
- Break a part probes – detect gene fusion > Dual colour probe – abnormal translocation, probe broken apart
KMT2A – doesn’t matter what its fused with just the translocation isn’t good
Digital Droplet PCR
very sensitive > probe for mutant and Wt added to PCR action components – partitioned into oil droplets one PCR reaction per droplet
WT probe only binds to WT and same for mutant
Measured by fluorescent detection
- Can predict relapse
Next generation sequencing
look at technique used for myeloid panel look for specific mutation s not shown in karyotyping
- More at once
Purpose of genetic testing
Prognostic
Diagnostic
Monitoring
Real time quantitative PCR
quantify DNA molecules present- used to monitor response to therapy
BCR-ABL Quantitation
Q-PCR is used to measure BCR/ABL transcript in monitoring of disease during treatment in CML
Chronic Myeloid Leukaemia (CML)
1960 Nowell and Hungerford
Small chromosome named the Philadelphia chromosome (Ph)
First evidence for a consistent chromosome change
1970 introduction of banding
PH Translocation
Fusion of two genes:
ABL1 (9q34)
BCR (22q11)
ABL1 is a cellular oncogene and encodes a nuclear tyrosine kinase protein
BCR/ABL1 gives an abnormal fusion protein with increased tyrosine kinase activity
Is a positive regulator of cell growth and leads to increased proliferation and malignant growth
Alone, is sufficient to cause CML
Targeted therapy for BCR-ABL1
2001- introduction of Imatinib
Specific inhibitor of of tyrosine kinase domain of ABL1
Blocks the binding site for ATP and inhibits phosphorylation
Prevents activation of the signal transduction pathways